Skip to main content
SpringerLink
Log in

Concomitant CYP3A4 inhibitors and calcium channel antagonist therapy is associated with an increased risk of adverse drug reactions

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Yoshida M, Matsumoto T, Suzuki T, Kitamura S, Mayama T.Effect of concomitant treatment with a CYP3A4 inhibitor and a calcium channel blocker. Pharmacoepidemiology and Drug Safety 17: 70-75, No. 1, Jan 2008

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Concomitant CYP3A4 inhibitors and calcium channel antagonist therapy is associated with an increased risk of adverse drug reactions. React. Wkly. 1190, 4 (2008). https://doi.org/10.2165/00128415-200811900-00012

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200811900-00012

Keywords

Search

Navigation